Cargando…
Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845115/ https://www.ncbi.nlm.nih.gov/pubmed/26475299 http://dx.doi.org/10.1161/JAHA.115.001991 |
Ejemplares similares
-
Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012) -
Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011) -
Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes
por: Mahajan, Rajiv
Publicado: (2009) -
Timed Bromocriptine-QR Therapy Reduces Progression of Cardiovascular Disease and Dysglycemia in Subjects with Well-Controlled Type 2 Diabetes Mellitus
por: Chamarthi, Bindu, et al.
Publicado: (2015) -
Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes
por: Gaziano, J. Michael, et al.
Publicado: (2010)